Tissue scaffolds functionalized with therapeutic elastin‐like biopolymer particles. Issue 5 (30th January 2020)

• Record Type: Journal Article
• Authors: Bulutoglu, Beyza; Devalliere, Julie; Deng, Sarah L.; Acun, Aylin; Kelangi, Sarah S.; Uygun, Basak E.; Yarmush, Martin L.
• Is Part Of: Biotechnology and bioengineering. Volume 117:Issue 5(2020)
• Page Start: 1575
• Page End: 1583
• Publication Date: 2020-01-30
• Subjects: alloderm -- elastin‐like polypeptides -- keratinocyte growth factor -- mouse pouch model -- tissue scaffolds; Biotechnology -- Periodicals; Bioengineering -- Periodicals; 660.6
• DOI: 10.1002/bit.27283
• Languages: English
• ISSNs: 0006-3592

Abstract

Abstract: Tissue engineering scaffolds are intended to provide mechanical and biological support for cells to migrate, engraft and ultimately regenerate the tissue. Development of scaffolds with sustained delivery of growth factors and chemokines would enhance the therapeutic benefits, especially in wound healing. In this study, we incorporated our previously designed therapeutic particles, composed of fusion of elastin‐like peptides (ELPs) as the drug delivery platform to keratinocyte growth factor (KGF), into a tissue scaffold, alloderm. The results demonstrated that sustained KGF–ELP release was achieved and the bioactivity of the released therapeutic particles was shown via cell proliferation assay, as well as a mouse pouch model in vivo, where higher cellular infiltration and vascularization were observed in scaffolds functionalized with KGF–ELPs. Abstract : Tissue scaffolds functionalized with therapeutic biomaterials composed of elastin‐like peptides (ELPs) and keratinocyte growth factor (KGF) are presented, allowing for sustained delivery of the growth factor. KGF‐ELP incorporated tissue scaffolds demonstrated higher cellular infiltration and vascularization in vivo, compared to recombinant KGF and non‐functionalized scaffolds, demonstrating the advantage of the ELP‐based delivery platform. These findings suggest that combining therapeutic ELP particles with tissue scaffolds can increase the clinical translatability of these biomaterials.